- Starpharma (SPL) will relaunch antiviral nasal spray VIRALEZE in the UK following the resolution of queries raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA)
- In June 2021, Starpharma’s UK retail partner LloydsPharmacy received correspondence from the MHRA in relation to specific promotional claims made for VIRALEZE
- The correspondence related to references to SARS-CoV-2 and COVID-19 and the interrelationship between these products claims and its categorisation
- The queries were successfully resolved and Starpharma is in the process of finalising the relaunch with preparations for product supply underway
- Starpharma is up 6.08 per cent on the market with shares trading at 96 cents
Starpharma (SPL) will relaunch its antiviral nasal spray VIRALEZE in the UK following the resolution of queries raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
In June 2021, Starpharma’s UK retail partner LloydsPharmacy received correspondence from the MHRA in relation to specific promotional claims made for VIRALEZE.
The correspondence related to promotional claims including references to SARS-CoV-2 and COVID-19 and the interrelationship between these products claims and its categorisation.
As a result, VIRALEZE sales were temporarily paused in the UK as the matter was resolved.
The queries were successfully resolved and Starpharma is in the process of finalising the relaunch with preparations for product supply underway.
In preparations for the relaunch, Starpharma has been in discussions with LloydsPharmacy with the product expected to be available online and instore.
“We are delighted to be relaunching VIRALEZE in the UK. We look forward to
making VIRALEZE available to UK consumers again very soon,” CEO Dr Jackie Fairley said.
“VIRALEZE is registered in more than 30 countries, and we look forward to rolling the product out into further markets this year.”
VIRALEZE contains antiviral agent SPL7013 which works by slowing down the infection of host cells before and after exposure to respiratory viruses.
From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.
Starpharma was up 6.08 per cent on the market with shares trading at 96 cents at 11:53 am AEDT.